Literature DB >> 31538528

Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease.

Stefano Ballestri1, Alessandro Mantovani2, Fabio Nascimbeni3, Simonetta Lugari4, Amedeo Lonardo3.   

Abstract

This review article aims to synthesize the evidence regarding nonalcoholic fatty liver disease (NAFLD) as a systemic disorder. We critically discuss the metabolic syndrome and its components; the cardiovascular and the endocrine system; chronic respiratory disorders; the musculoskeletal system; the skin; and extra-hepatic tumors. We conclude that, while some of these extra-hepatic conditions clearly predispose to the development of secondary forms of NAFLD (typically hypothyroidism-induced NAFLD), others result from pre-existent NAFLD (e.g., certain extra-hepatic tumors) and others (such as Type 2 Diabetes) have, with NAFLD, mutual and bidirectional associations. Analyzed data imply that NAFLD is not merely a hepatic disease. It is also and possibly more importantly, a systemic disorder requiring a special awareness, a multidisciplinary approach and a multidimensional vision.

Entities:  

Keywords:  PCOS; bone mass density; cancer; cardiovascular system; endocrine system; large bowel; metabolic syndrome; sarcopenia; uric acid

Mesh:

Year:  2019        PMID: 31538528     DOI: 10.4155/fmc-2019-0003

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  18 in total

1.  The "obese liver" and gastrointestinal cancer risk.

Authors:  Amedeo Lonardo; Luca Roncucci
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

2.  Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

Authors:  Tiantian Song; Yujiao Jia; Zelin Li; Fei Wang; Luping Ren; Shuchun Chen
Journal:  Diabetes Ther       Date:  2021-05-17       Impact factor: 2.945

3.  Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease.

Authors:  Lei Miao; Li Yang; Li-Sha Guo; Qiang-Qiang Shi; Teng-Fei Zhou; Yang Chen; Huai Zhang; Hui Cai; Zhi-Wei Xu; Shuan-Ying Yang; Hai Lin; Zhe Cheng; Ming-Yang Zhu; Xu Nan; Shuai Huang; Ya-Wen Zheng; Giovanni Targher; Christopher D Byrne; Yu-Ping Li; Ming-Hua Zheng; Cheng-Shui Chen
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

Review 4.  Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research.

Authors:  Amedeo Lonardo; Ayako Suzuki
Journal:  J Clin Med       Date:  2020-04-28       Impact factor: 4.241

Review 5.  Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options.

Authors:  Daniela Maria Tanase; Evelina Maria Gosav; Ecaterina Neculae; Claudia Florida Costea; Manuela Ciocoiu; Loredana Liliana Hurjui; Claudia Cristina Tarniceriu; Mariana Floria
Journal:  Int J Mol Sci       Date:  2020-08-18       Impact factor: 5.923

Review 6.  History of Nonalcoholic Fatty Liver Disease.

Authors:  Amedeo Lonardo; Simona Leoni; Khalid A Alswat; Yasser Fouad
Journal:  Int J Mol Sci       Date:  2020-08-16       Impact factor: 5.923

Review 7.  Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management.

Authors:  Amedeo Lonardo; Juan Pablo Arab; Marco Arrese
Journal:  Adv Ther       Date:  2021-04-07       Impact factor: 3.845

8.  The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Shelley E Harris; Toryn M Poolman; Anastasia Arvaniti; Roger D Cox; Laura L Gathercole; Jeremy W Tomlinson
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-08-05       Impact factor: 4.052

9.  Methodological Tools for Exploring Novel Biopharmaceutical Approaches to the Metabolic Syndrome and Related Disorders : A Commentary on: Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. A Focus on Early Phase Clinical Drug Development, Second Edition.

Authors:  Amedeo Lonardo; Enrica Baldelli
Journal:  Diabetes Ther       Date:  2020-03-07       Impact factor: 2.945

Review 10.  Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review.

Authors:  Stefano Ballestri; Mariano Capitelli; Maria Cristina Fontana; Dimitriy Arioli; Elisa Romagnoli; Catia Graziosi; Amedeo Lonardo; Marco Marietta; Francesco Dentali; Giorgio Cioni
Journal:  Adv Ther       Date:  2020-04-13       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.